Abstracts tagged "Gastrointestinal complications and rheumatoid arthritis (RA)"

Abstract Number: 228 • 2018 ACR/ARHP Annual Meeting
Widespread Chronic Use of Proton-Pump Inhibitors and Potential for Drug-Drug Interactions in Rheumatoid Arthritis and Lupus Patients
Daniel Keebler¹, Nicholas Jones¹ and Matthew McEnany², ¹Genentech, Inc., South San Francisco, CA, ²Genesis Research, Hoboken, NJ
Background/Purpose: Poor control of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) can lead to the use of corticosteroids and non-steroidal anti-inflammatories (NSAIDs), which in…
Abstract Number: 960 • 2018 ACR/ARHP Annual Meeting
The Risk of Gastrointestinal Perforations Associated with Biologic Disease-Modifying Anti-Rheumatic Drugs Used in Rheumatoid Arthritis: A Nationwide Swedish Cohort Study
Andrei Barbulescu¹, Thomas Frisell¹, Johan Askling² and Bénédicte Delcoigne¹, ¹Clinical Epidemiology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ²Unit of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Gastrointestinal (GI) perforations occur more often than expected in patients with RA. Reports indicate that tocilizumab may be associated with an increased risk of…
Abstract Number: 1414 • 2014 ACR/ARHP Annual Meeting
Investigation of the Association Between Gastroesophageal Reflux Disease and Clinical Factors in Patients with Rheumatoid Arthritis
Katsushi Ishii¹, Yuichi Mochida¹, Yuki Ozawa¹, Naoto Mitsugi² and Tomoyuki Saito³, ¹Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, ²Orthopaedic Surgery, Yokohama City University Medical Center, Yokohama, Japan, ³Orthopaedic Surgery, Yokohama City University School of Medicine, Yokohama, Japan
Background/Purpose: Gastroesophageal reflux disease (GERD) is caused by the abnormal reflux of the gastric contents into the esophagus. Many risk factors are considered as a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].